Get the Stockscreener App
91.05
1.38%
-1.27
After Hours:
89.23
-1.82
-2.00%
Mirum Pharmaceuticals Inc stock is traded at $91.05, with a volume of 335.50K.
It is down -1.38% in the last 24 hours and up +35.79% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$92.32
Open:
$93.7
24h Volume:
335.50K
Relative Volume:
0.50
Market Cap:
$4.71B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-56.48
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
+5.18%
1M Performance:
+35.79%
6M Performance:
+72.44%
1Y Performance:
+98.67%
1-Day Range:
$90.86
$93.70
1-Week Range:
$82.00
$93.70
52-Week Range:
$36.88
$93.70
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
91.05 | 4.77B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum Stock Rises 7% in a Week: Here's What You Should Know - TradingView — Track All Markets
Mirum Pharmaceuticals stock soars to all-time high of $48.94 - MSN
Mirum Pharmaceuticals stock hits all-time high at 91.99 USD By Investing.com - Investing.com India
Mirum Pharmaceuticals stock hits all-time high at 91.99 USD - Investing.com
HC Wainwright Has Bullish Estimate for MIRM FY2025 Earnings - MarketBeat
Citizens reiterates Market Outperform rating on Mirum Pharmaceuticals stock By Investing.com - Investing.com UK
Income Plays: How correlated is MSPRK to the S P500July 2025 Volume & Expert Curated Trade Setup Alerts - baoquankhu1.vn
MIRM: Four pivotal clinical readouts and robust revenue growth position the pipeline for major expansion - TradingView — Track All Markets
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 - AOL.com
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
MarketsMedicine Hat News - FinancialContent
Aug Highlights: Is Mirum Pharmaceuticals Inc 08D stock undervalued after correctionQuarterly Market Summary & Weekly High Return Stock Forecasts - Bộ Nội Vụ
3 Top Growth Stocks to Buy in the First Half of 2026 - Finviz
Mirum Pharmaceuticals, Inc. (MIRM) Investor Outlook: Promising Upside with 47.2% Revenue Growth - DirectorsTalk Interviews
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Baird raises Mirum Pharmaceuticals stock price target to $95 on strong sales - Investing.com Canada
Mirum Pharmaceuticals reports $520 million in 2025 net product sales By Investing.com - Investing.com Nigeria
Baird Adjusts Mirum Pharmaceuticals Price Target to $95 From $88, Maintains Outperform Rating - marketscreener.com
Mirum Pharmaceuticals stock exceeds FY25 guidance, TD Cowen reiterates Buy By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals stock exceeds FY25 guidance, TD Cowen reiterates Buy - Investing.com Nigeria
Mirum Pharmaceuticals announces preliminary unaudited 2025 results, demonstrating strong commercial growth and pipeline momentum - marketscreener.com
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum - TradingView — Track All Markets
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum - Yahoo Finance
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - marketscreener.com
Will strong Livmarli uptake continue to aid MIRM's revenues in 2026? - MSN
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price Is Right But Growth Is Lacking After Shares Rocket 34% - 富途牛牛
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug - Investing.com Nigeria
Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Update & High Conviction Buy Zone Alerts - Улправда
Can Mirum Pharmaceuticals Inc. (08D) stock test all time highsTrade Performance Summary & Weekly Hot Stock Watchlists - ulpravda.ru
Is Mirum Pharmaceuticals Inc. (08D) stock undervalued after correctionJuly 2025 Institutional & Risk Managed Investment Entry Signals - Улправда
Will Mirum Pharmaceuticals Inc. stock benefit from infrastructure spendingWeekly Stock Report & Risk Controlled Daily Plans - Улправда
How supply chain issues affect Mirum Pharmaceuticals Inc. stockJuly 2025 Action & Fast Gaining Stock Reports - Улправда
Can Mirum Pharmaceuticals Inc. stock reach $100 price targetQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Mirum Pharmaceuticals to raise $68.5M in private placement with TCGX - MSN
Mirum Pharmaceuticals stock hits all-time high at 82.65 USD By Investing.com - Investing.com Nigeria
How Investors May Respond To Mirum Pharmaceuticals (MIRM) Expanding Livmarli And Gaining J.P. Morgan Spotlight - Yahoo Finance
Is Mirum Pharmaceuticals Inc. stock supported by strong fundamentalsInstitutional Holding Changes & High Return Investment Plans - Улправда
Mirum Pharmaceuticals, Inc.common stock (NQ: MIRM - FinancialContent
How Mirum Pharmaceuticals Inc. stock compares to growth peersMorning Star Patterns & Free Skyrocketing Profit Margins - Улправда
Should you invest in Mirum Pharmaceuticals (MIRM)? - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) Hits New 12-Month HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Mirum Pharmaceuticals stock hits all-time high at 82.65 USD - Investing.com India
What hedge fund activity signals for Mirum Pharmaceuticals Inc. stockEarnings Date Calendar & Low Cost Trading Plans - ulpravda.ru
Mirum Pharmaceuticals (MIRM) price target increased by 16.25% to 104.35 - MSN
Should You Invest in Mirum Pharmaceuticals (MIRM)? - Finviz
Gains Recap: Will Mirum Pharmaceuticals Inc stock benefit from infrastructure spendingWeekly Investment Summary & Short-Term High Return Strategies - Bộ Nội Vụ
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):